CLOSE
MENU
Row of black office chairs in meeting room
Row of black office chairs in meeting room

Board of Directors

Thomas W. Ross, Sr., Lead Independent Director

Thomas W. Ross, Sr.

Chairman of the Board

Mr. Ross was named Bausch + Lomb Chairman of the Board in July 2022. He has served as the President of Volcker Alliance since July 2016, where he is also a director. He is President Emeritus of the University of North Carolina (UNC), having served as President from 2011 to January 2016. He was named the Sanford Distinguished Fellow in Public Policy at the Duke University Sanford School of Public Policy in 2016 and continues to serve in that role. Prior to becoming President of the UNC system, Mr. Ross served as President of Davidson College, Executive Director of the Z. Smith Reynolds Foundation, director of the North Carolina Administrative Office of the Courts, a Superior Court judge, chief of staff to U.S. Congressman Robin Britt, a member of the Greensboro, NC law firm Smith, Patterson, Follin, Curtis, James & Harkavy and Assistant Professor of Public Law and Government at UNC Chapel Hill’s School of Government. He also serves as Corporate Director of the Board of Directors for Bausch Health Companies. Mr. Ross holds a B.A. in Political Science from Davidson College and a J.D. from University of North Carolina School of Law.

Nathalie Bernier, Independent Director

Nathalie Bernier

Independent Director

From August 2015 to September 2019, Ms. Bernier served as Chief Financial Officer and Senior Vice President Strategic and Business Planning of Public Sector Pension Investment Board, a large Canadian pension investment manager. Prior to this role, Ms. Bernier spent nearly 30 years as an Audit and Advisory Partner at Arthur Andersen LLP and KPMG from 1986 to 2015, including serving as Regional Managing Partner (Quebec) and as a member of KPMG’s Canadian Leadership team. Ms. Bernier is currently a director of RF Capital Group Inc., a publicly traded company, where she serves as Chairperson of the risk committee and member of the audit committee. Ms. Bernier also currently serves as a director of the board of Canada Enterprise Emergency Funding Corporation, a Canadian Crown Corporation, where she serves as Chairperson of the audit committee. Ms. Bernier is also Chairperson of the board of United Way of Greater Montreal Foundation, a charitable organization. Ms. Bernier holds a Bachelor of Commerce degree from McGill University. She is a Certified Public Accountant and a fellow of the Chartered Professional Accountants in Canada.

Andrew C. von Eschenbach, Independent Director

Andrew C. von Eschenbach

Independent Director

Dr. von Eschenbach has been President of Samaritan Health Initiatives, Inc., a health care policy consultancy, and an Adjunct Professor at University of Texas MD Anderson Cancer Center, since 2010. From 2005 to 2009, Dr. von Eschenbach served as Commissioner of the U.S. Food and Drug Administration (FDA) and before that served four years as Director of the National Cancer Institute at the National Institutes of Health. As a researcher, clinician and administrator, Dr. von Eschenbach served for twenty-six years at the University of Texas MD Anderson Cancer Center as Chairman of Urology, Director of the Prostate Cancer Research Program and Executive Vice President and Chief Academic Officer. He earned a B.S. from St. Joseph’s University and a medical degree from Georgetown University School of Medicine in Washington, D.C. He completed his residency in surgery and urology at Pennsylvania Hospital and University of Pennsylvania, respectively, and his urologic oncology fellowship at University of Texas MD Anderson Cancer Center.

Dr. von Eschenbach has served as a director of Radius Health, Inc., a publicly traded biopharmaceutical company, since January 2021. He has served as a director of Celularity, Inc., a private biotechnology company, and as a director of Wren Therapeutics, Ltd, a private biopharmaceutical company, since February 2018 and November 2019, respectively. He has been a member of the board of the Regan Udall Foundation of the FDA, a non-profit organization formed to advance regulatory science, since December 2018.

Sarah B. Kavanagh, Independent Director

Sarah B. Kavanagh

Independent Director

From 2011 through May 2016, Ms. Kavanagh served as a Commissioner of the Ontario Securities Commission, where she also served as Chairperson of the audit committee starting in 2014. Between 1999 and 2010, Ms. Kavanagh served in various senior investment banking roles at Scotia Capital Inc., including Vice-Chair and Co-Head of Diversified Industries Group, Head of Equity Capital Markets, and Head of Investment Banking. Prior to Scotia Capital, she held several senior financial positions with operating companies. She started her career as an Investment Banker with a bulge bracket firm in New York. Ms. Kavanagh graduated from Harvard Business School with a Master of Business Administration and received a Bachelor of Arts degree in Economics from Williams College.

Since 2013, Ms. Kavanagh has been a Director of Hudbay Minerals Inc., a publicly traded Canadian mining corporation, and a member of the board of trustees of WPT Industrial REIT, a publicly traded open-ended real estate investment trust. In addition to her public company directorships, she is a Director of AST and AST Trust Company (Canada) (formerly Canadian Stock Transfer Company) and serves as a Director of Sustainable Development Technology Canada and Cymax Group Technologies. She completed the Directors Education Program at the Institute of Corporate Directors in 2011. Ms. Kavanagh has also served on the board of Bausch Health Companies since July 2016.

Joseph C. Papa, Chief Executive Officer

Joseph C. Papa

Chief Executive Officer

Joseph C. Papa has more than 35 years of experience in the pharmaceutical, health care and specialty pharmaceutical industries, including more than 20 years of branded prescription drug experience.

Before joining Bausch + Lomb, Mr. Papa was the Chief Executive Officer and Chairman of the Board of Bausch Health Companies Inc. ("Bausch Health") from 2016 to 2022. Previously, he was the Chief Executive Officer of the Perrigo Company from 2006 to 2016. He also served as Chairman and Chief Executive Officer of Cardinal Health's Pharmaceutical Technologies and Services business unit from 2004 to 2006. Prior to that, he was President and Chief Operating Officer for Watson Pharmaceuticals from 2001 to 2004, President of Global Country Operations for Pharmacia's North American business from 2000 to 2001 and President of Searle's U.S. Operations from 1997 to 2000. Before that, he served in various general management, sales, marketing and R&D positions during his 15-year career at Novartis Pharmaceuticals Corporation from 1983 to 1997. He led teams that successfully launched several blockbuster pharmaceutical products, including Lotrel, Diovan and Celebrex, and he is the patent holder for a cardiovascular combination treatment containing Amlodipine and Benazepril.

In 2014, Harvard Business Review ranked Mr. Papa 47th on its "2014 Best Performing CEOs in the World." list. He was also recognized on Israel-based Calcalist magazine's "Best Chief Executive Officer for the Year" list for 2013 and 2014. Additionally, he was named one of the World's Best CEOs by Barron's in 2012, which noted Perrigo "generated one of the best shareholder returns in the S&P 500 in the past five years."

Mr. Papa also serves as Lead Independent Director and Chairman of the Compensation Committee for Prometheus Biosciences. He is a past member of the UConn Foundation Board of Directors and the Smith & Nephew Board of Directors, where he served as Chairman of the Remuneration Committee.

Mr. Papa holds a Bachelor of Science in Pharmacy from the University of Connecticut and an MBA from Northwestern University's Kellogg Graduate School of Management. In 2012, he received an Honorary Doctor of Science degree from the University of Connecticut's School of Pharmacy.

John A. Paulson, Independent Director

John A. Paulson

Independent Director

Mr. Paulson is the President and Portfolio Manager of Paulson & Co. Inc., an SEC-registered investment management company specializing in global mergers, event arbitrage and credit strategies, which he founded in 1994. Prior to forming Paulson & Co. Inc., Mr. Paulson was a Partner of Gruss Partners and a Managing Director in mergers and acquisitions at Bear Stearns. Mr. Paulson received his undergraduate degree from New York University in 1978 and his Master of Business Administration from Harvard Business School in 1980. Mr. Paulson has been a Director of BrightSphere Investment Group Inc., a publicly traded asset management holding company, since November 2018, and has served as Chairman since April 2020. He also currently serves as a member of the Advisory Board of Harvard Business School. He previously served as a Director of American International Group Inc. from May 2016 to June 2017. In June 2022, Mr. Paulson was appointed Chairperson of the Board for Bausch Health.

Russel C. Robertson, Independent Director

Russel C. Robertson

Independent Director

From 2013 through August 2016, Mr. Robertson served as Executive Vice President and Head, Anti-Money Laundering, at BMO Financial Group, a diversified financial services organization. Prior to that role, he served as BMO’s Executive Vice President, Business Integration, and as Vice Chair. He joined BMO as interim Chief Financial Officer in 2008 and was appointed Chief Financial Officer in 2009. Before joining BMO, Mr. Robertson spent more than 35 years as a Chartered Public Accountant. In this capacity, he held various senior positions with a number of major accounting firms, including Vice Chair, Deloitte & Touche LLP in Toronto, Canada, from 2002 to 2008, and Canadian Managing Partner, Arthur Andersen LLP, from 1994 to 2002. Mr. Robertson holds a Bachelor of Arts degree (Honours) from the Ivey School of Business at the University of Western Ontario.

Mr. Robertson has served on the board of Hydro One Limited, a publicly traded electricity transmission and distribution utility serving Ontario, since August 2018, and since 2012 has served on the board of Turquoise Hill Resources, a publicly traded Canadian mineral exploration and development company. He has also been serving on the board of Bausch Health Companies since June 2016. Mr. Robertson previously served on the board of Virtus Investment Partners, Inc. from 2013 to August 2016.

Richard U. De Schutter, Independent Director

Richard U. De Schutter

Independent Director

Mr. De Schutter is the owner of asset management firm L.B. Gemini, Inc., where he has served as President and Director since 2000. He previously served as the Chairman and CEO of DuPont Pharmaceuticals Company from July 2000 until its acquisition by Bristol-Myers Squibb in October 2001. Mr. De Schutter was also a Director and Chief Administrative Officer of Pharmacia Corporation, which was created through the merger of Monsanto Company and Pharmacia & Upjohn in 2000. Prior to this merger, he was a Director, Vice Chairman and Chief Administrative Officer for Monsanto. From 1995 to 1999, he served as Chairman and CEO of G.D. Searle & Co., Monsanto’s wholly owned pharmaceutical subsidiary. Mr. De Schutter earned a Bachelor of Science degree and a Master of Science Degree in Chemical Engineering from the University of Arizona.

Mr. De Schutter has served as a Director of AuVen Therapeutics since 2007, and as a Director of Sermonix Pharmaceuticals Inc. since April 2019. He previously served as Chairman Incyte Corporation, from 2003 to 2015, and Durata Therapeutics, Inc., from 2012 to 2014. He served as a Director of Smith & Nephew plc from 2001 to 2014, during which time he served as Lead Independent Director from 2011 to 2014. Since 2017, Mr. De Schutter has also served on the board of Bausch Health Companies.

Brett Icahn, Portfolio Manager, Icahn Capital LP

Brett Icahn

Portfolio Manager, Icahn Capital LP

Mr. Icahn joined the Bausch + Lomb board in June 2022. He has been a portfolio manager for Icahn Capital LP since October 2020. Icahn Capital LP is a subsidiary of Icahn Enterprises L.P., a diversified holding company engaged in a variety of businesses, including investment, automotive, energy, food packaging, metals, real estate and home fashion. Mr. Icahn has held a variety of investment advisory roles at Icahn Enterprises L.P. since 2002, including as an investment strategy consultant from 2017 to 2020, and as portfolio manager of the Sargon Portfolio from 2010 to 2017. He previously served on the board of Bausch Health from 2021 to 2022 and has also served on the board of Icahn Enterprises L.P., a private entity since 2020. He has also been a director of Newell Brands Inc., a publicly traded global marketer of consumer and commercial products, since 2018 and Dana Inc., a supplier of automotive products and services, since January 2022. Mr. Icahn was previously a director of Nuance Communications, Inc., a provider of voice and language solutions, from 2013 to 2016. He also previously served on the boards of American Railcar Industries, Inc., Take-Two Interactive Software Inc., The Hain Celestial Group, Inc. and Voltari Corporation. Mr. Icahn received a B.A. from Princeton University.

Gary Hu, Portfolio Manager, Icahn Capital LP

Gary Hu

Portfolio Manager, Icahn Capital LP

Mr. Hu joined the Bausch + Lomb board in June 2022 and has been a portfolio manager for Icahn Capital LP since October 2020. Prior to joining Icahn Capital LP, Mr. Hu held a variety of investment management roles from 2012 to 2020 at Silver Point Capital LP, a credit-focused investment firm, and from 2010 to 2012 at Stockbridge Investors, the public securities affiliate of Berkshire Partners LLC. Mr. Hu has served on the board of Dana Incorporated since January 2022. He was previously on the boards of Occidental Petroleum Corporation from 2021 to March 2022 and Cloudera Inc. from January to October 2021. Mr. Hu graduated from the University of Pennsylvania with a B.S. Econ in Finance and Accounting from The Wharton School and a B.A.S. in Computer Science from the School of Engineering and Applied Science.